Results 11 to 20 of about 9,917 (88)

Osteomalacia oncogénica secundaria a tumor mesenquimal fosfatúrico del pie

Revista Colombiana de Reumatología, 2020
María Eugenia Reguero-Callejas, Mónica Vázquez-Díaz, Sandra Garrote-Corral, Walter Alberto Sifuentes-Giraldo   +3 more
core   +2 more sources

Osteomalacia oncogénica como manifestación paraneoplásica de un tumor fosfatúrico mesenquimal de la columna vertebral

Revista Colombiana de Hematología y Oncología, 2022
Objetivo: reportar el caso de una paciente con sintomatología osteomuscular de larga data con diagnóstico final de osteomalacia oncogénica por tumor fosfatúrico mesenquimal.
Alicia Quiroga Echeverri, L. G. González Pérez, I. C. Durango, Gustavo Adolfo Giraldo García, Germán Alonso Reyes Botero, Alejandro Vélez Hoyos, Gabriel Jaime Varela Aguirre   +6 more
semanticscholar   +1 more source

Osteomalacia in Adults: A Practical Insight for Clinicians

Journal of Clinical Medicine, 2023
The term osteomalacia (OM) refers to a series of processes characterized by altered mineralization of the skeleton, which can be caused by various disorders of mineral metabolism. OM can be genetically determined or occur due to acquired disorders, among
L. Arboleya, Ignacio Braña, E. Pardo, Marta Loredo, R. Queiró   +4 more
semanticscholar   +1 more source

Global guidance for the recognition, diagnosis, and management of tumor‐induced osteomalacia

Journal of Internal Medicine, 2022
Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by mesenchymal tumors that secrete fibroblast growth factor 23 (FGF23). Patients present with progressive bone pain, muscle weakness, and fragility fractures.
S. M. Jan de Beur, S. Minisola, W. Xia, B. Abrahamsen, J. Body, M. Brandi, R. Clifton-Bligh, M. Collins, P. Florenzano, P. Houillier, Y. Imanishi, E. Imel, Aliya A. Khan, M. Zillikens, Seiji Fukumoto   +14 more
semanticscholar   +1 more source

TUMOR-INDUCED OSTEOMALACIA: A COMPREHENSIVE REVIEW.

Endocrine reviews, 2022
Tumor-induced osteomalacia (TIO) is an ultrarare paraneoplastic syndrome due to overproduction of fibroblast growth factor 23 (FGF23), with profound effects on the morbidity of the patients affected.
S. Minisola, S. Fukumoto, Weibo Xia, A. Corsi, L. Colangelo, A. Scillitani, J. Pepe, C. Cipriani, R. Thakker   +8 more
semanticscholar   +1 more source

Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports

Journal of Bone and Mineral Research, 2022
Randomized control trials (RCTs) have shown that certain intravenous iron preparations can induce high levels of fibroblast growth factor 23 (FGF‐23) and persistent hypophosphatemia.
T. Vilaca, Nalini Velmurugan, Christopher D. Smith, B. Abrahamsen, R. Eastell   +4 more
semanticscholar   +1 more source

Tumor induced osteomalacia: a systematic review and individual patient's data analysis.

Journal of Clinical Endocrinology and Metabolism, 2022
CONTEXT Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome, usually caused by small, benign and slow-growing phosphaturic mesenchymal tumors.
D. Rendina, V. Abate, Giuseppe Cacace, L. D. Elia, G. De Filippo, S. Del Vecchio, F. Galletti, A. Cuocolo, P. Strazzullo   +8 more
semanticscholar   +1 more source

Osteomalacia Is Not a Single Disease

International Journal of Molecular Sciences, 2022
Among bone-material qualities, mineralization is pivotal in conferring stiffness and toughness to the bone. Osteomalacia, a disease ensuing from inadequate mineralization of the skeleton, is caused by different processes leading to decreased available ...
L. Cianferotti
semanticscholar   +1 more source

Long-term use of burosumab for the treatment of tumor-induced osteomalacia

Osteoporosis International, 2022
Summary Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by tumoral overproduction of FGF-23. Due to local recurrence, we describe the long-term efficacy and safety profile of burosumab, an anti-FGF-23 monoclonal antibody, in a ...
C. Crotti, F. Zucchi, C. Alfieri, R. Caporali, M. Varenna   +4 more
semanticscholar   +1 more source

Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience

Journal of the Endocrine Society, 2021
Purpose Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome of abnormal phosphate and vitamin D metabolism caused by typically small endocrine tumors that secrete fibroblast growth factor 23 (FGF23).
K. Dahir, M. Zanchetta, I. Stanciu, C. Robinson, Janet Y. Lee, R. Dhaliwal, J. Charles, R. Civitelli, M. S. Roberts, S. Krolczyk, T. Weber   +10 more
semanticscholar   +1 more source